Transplantation for non-Hodgkin lymphoma

Expert Review of Hematology

Volumn 2, Issue 4, 2009, Pages 425-442

  Nademanee, Auayporn ^a  

^a Division of Hematology and Hematopoietic Cell Transplantation   (United States)

Author keywords

Allogeneic stem cell transplant; Autologous stem cell transplant; Non Hodgkin lymphoma

Indexed keywords

BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLINIC ACID; IBRITUMOMAB TIUXETAN; MELPHALAN; METHOTREXATE; PREDNISONE; RITUXIMAB; TENIPOSIDE; TOSITUMOMAB I 131; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HUMAN; MANTLE CELL LYMPHOMA; MORTALITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOTHERAPY; REDUCED INTENSITY CONDITIONING; REVIEW; T CELL LYMPHOMA; TREATMENT FAILURE; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN;

EID: 77953412373     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.24     Document Type: Review

References (100)

1. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N. Engl. J. Med. 316, 1493-1498 (1987).
2. Weaver CH, Petersen FB, Appelbaum FA et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J. Clin. Oncol. 12, 2559-2566 (1994).
3. Brown JR, Yeckes H, Friedberg JW et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J. Clin. Oncol. 23, 2208-2214 (2005).
4. Darrington DL, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogeneous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J. Clin. Oncol. 12, 2527-2534 (1994).
5. Hamlin PA, Zelenetz AD, Kewalramani T et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102, 989-1996 (2003).
6. Spaepen K, Stroobants S, Dupont P et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ( [18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J. Clin. Oncol. 19, 414-419 (2001).
7. Alousi A, Saliba RM, Okoroji GJ et al. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplant. Br. J. Haematol. 142, 786-792 (2008).
8. Filmont L-E, Gisselbrecht C, Cuenca X et al. The impact of pre-and posttransplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 110, 1361-1369 (2009).
9. Derenzini E, Musuraca G, Fanti S et al. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer 113, 2496-2503 (2008).
10. Schot BW, Zijlstra JM, Sluiter WJ et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 109, 486-491 (2007).
11. Nyman H, Adde M, Karjalainen-Lindsberg ML et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109(11), 4930-4935 (2007).
12. Moskowitz CH, Zelenetz AD, Kewalramani T et al. Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 106(10), 3383-3385 (2005).
13. Costa LJ, Feldman AL, Micallef INM et al. Germinal center B (GCB) and non GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. Br. J. Haematol. 142, 404-412 (2008).
14. Vellenga E, van Putten WL, van 't Veer MB et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 111, 537-543 (2008).
15. Khouri IF, Saliba RM, Hosing C et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 23, 2240-2247 (2005).
16. Horwitz SM, Negrin RS, Blume KG et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 103, 777-783 (2004).
17. Tarella C, Zanni M, Magni M et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innovative Nei Linfomi survey. J. Clin. Oncol. 26, 3166-3175 (2008).
18. Press OW, Eary JF, Appelbaum FR et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329, 1219-1224 (1993).
19. Press OW, Eary JF, Gooley T et al. A Phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96, 2934-2942 (2000).
20. Liu SY, Eary JF, Petersdorf SH et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antobody and autologous stem cell rescue. J. Clin. Oncol. 16(10), 3270-3278 (1998).
21. Gopal AK, Rajendran JG, Gooley TA et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults >= 60 years old with relapsed or refractory B-cell lymphoma. J. Clin. Oncol. 25(11), 1396-1402 (2007).
22. Nademanee A, Forman S, Molina A et al. A Phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106, 2896-2902 (2005).
23. Nademanee A, Raubitschek A, Molina A et al. Updated results of high-dose yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (vp-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (ahsct) for poor-risk or refractory B-cell non-Hodgkin's lymphoma. ASH Annual Meeting Abstracts. Blood 110, (2007) (Abstract 1891).
24. Winter JN, Inwards DJ, Spies S et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose beam and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 27, 1653-1659 (2009).
25. Devizzi L, Guidetti A, Tarella C et al. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J. Clin. Oncol. 26, 5175-5182 (2008).
26. Ferrucci PF, Vanazzi A, Grana CM et al. High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/ resistant B-cell non-Hodgkin lymphomas. Br. J. Haematol. 139, 590-599 (2007).
27. Vose JM, Bierman PJ, Enke C et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 23, 461-467 (2005).
28. Vose J, Bierman P, Bociek G et al. Radioimmunotherapy with 131-I tositumomab enhanced survival in good prognosis relapsed and high-risk diffuse large B-cell lymphoma (DLBCL) patients receiving high-dose chemotherapy and autologous stem cell transplantation. J. Clin. Oncol. 25, (2007) (Abstract 8013).
29. Krishnan A, Nademanee A, Fung HC et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 26, 90-95 (2008).
30. Shimoni A, Zwas ST, Oksman Y et al. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp. Hematol. 35, 534-540 (2007).
31. Alousi AM, Hosing C, Saliba RM et al. Zevalin(R)/BEAM/rituximab vs beam/ rituximab and autologous stem cell transplantation (ASCT) for relapsed chemosensitive diffuse large B-cell lymphoma (DLBCL): impact of the IPI and PET Status. ASH Annual Meeting Abstracts. Blood 110, (2007) (Abstract 620).
32. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective Lnh87-2 Protocol -a groupe d'Etude des lymphomes de l'Adulte study. J. Clin. Oncol. 18, 3025-3030 (2000).
33. Santini G, Salvagno L, Leoni P et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J. Clin. Oncol. 16, 2796-2802 (1998).
34. Milpied N, Deconinck E, Gaillard F et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N. Engl. J. Med. 350(13), 1287-1295 (2004).
35. Gisselbrecht C, Lepage E, Molina T et al. Shortened first-line high-dose chemotherapy for patients with poorprognosis aggressive lymphoma. J. Clin. Oncol. 20, 2472-2479 (2002).
36. Kaiser U, Uebelacker I, Abel U et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J. Clin. Oncol. 20, 4413-4419 (2002).
37. Martelli M, Gherlinzoni F, De Renzo A et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J. Clin. Oncol. 21, 1255-1262 (2003).
38. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized Phase III EORTC study. J. Natl. Cancer Inst. 93, 22-30 (2001).
39. Pfreundschuh M, Trümper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 7, 379-391 (2006).
40. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin. Oncol. 29(2), 18-22 (2002). (Pubitemid 34594980)
41. Peniket AJ, Ruiz de Elvira MC, Taghipour G et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 31, 667-678 (2003).
42. Freytes CO, Loberiza FR, Rizzo JD et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 104, 3797-3803 (2004).
43. Robinson SP, Goldstone AH, Mackinnon S et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100, 4310-4316 (2002).
44. Thomson KJ, Morris EC, Bloor A et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 27, 426-432 (2009).
45. Rezvani AR, Norasetthada L, Gooley T et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br. J. Haematol. 143, 395-403 (2008).
46. Schouten HC, Qian W, Kvaloy S et al. High-dose therapy improves progressionfree survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J. Clin. Oncol. 21, 3918-3927 (2003).
47. Montoto S, Canals C, Rohatiner AZ et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 21, 2324-2331 (2007).
48. Rohatiner AZ, Nadler L, Davies AJ et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J. Clin. Oncol. 25, 2554-2559 (2007).
49. Sebban C, Brice P, Delarue R et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J. Clin. Oncol. 26, 3614-3620 (2008).
50. Lenz G, Dreyling M, Schiegnitz E et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104, 2667-2674 (2004).
51. Gyan E, Foussard C, Bertrand P et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 113, 995-1001 (2009).
52. Sebban C, Mounier N, Brousse N et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 108, 2540-2544 (2006).
53. Ladetto M, De Marco F, Benedetti F et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111, 4004-4013 (2008).
54. Pham RN, Gooley TA, Keeney GE et al. The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma. Bone Marrow Transplant. 40, 1039-1044 (2007).
55. Vose JM, Bierman PJ, Loberiza FR et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and follicular international prognostic index. Biol. Blood Marrow Transplant. 14, 36-42 (2008).
56. Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 104(5), 1258-1265 (2004).
57. Keeney GE, Gooley TA, Pham RN et al. The pretransplant follicular lymphoma international prognostic index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation. Leuk. Lymphoma 48, 1961-1967 (2007).
58. Gopal AK, Gooley TA, Maloney DG et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 102, 2351-2357 (2003).
59. Gisselbrecht C, Decaudin D, Mounier N et al. 90Yttrium ibritumomab tiuxetan (zevalin) combined with beam (z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory follicular lymphoma. GELA Phase II study. ASH Annual Meeting Abstracts. Blood 110, (2007) (Abstract 22).
60. van Besien K, Loberiza FR Jr, Bajorunaite R et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102, 3521-3529 (2003). (Pubitemid 37409366)
61. Khouri IF, McLaughlin P, Saliba RM et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111, 5530-5536 (2008).
62. Morris E, Thomson K, Craddock C et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104, 3865-3871 (2004).
63. Maris MB, Sandmaier BM, Storer B et al. Allogeneic hematopoietic cell transplantation (hct) after nonmyeloablative conditioning for relapsed or refractory follicular lymphoma. ASH Annual Meeting Abstracts. Blood 106, (2005) (Abstract 1130).
64. Vigouroux S, Michallet M, Porcher R et al. Long-term outcomes after reducedintensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 92, 627-634 (2007).
65. Hari P, Carreras J, Zhang MJ et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol. Blood Marrow Transplant.14, 236-245 (2008).
66. Shimoni A, Zwas ST, Oksman Y et al. Ibritumomab tiuxetan (zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. Bone Marrow Transplant. 41, 355-361 (2007).
67. Gopal AK, Rajendran JG, Pagel JM et al. A Phase II trial of 90Y-ibritumomab tiuxetan-based reduced intensity allogeneic peripheral blood stem cell (PBSC) transplantation for relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL). ASH Annual Meeting Abstracts. Blood 108, (2006) (Abstract 316).
68. Khouri IF, Saliba RM, Hosing C et al. Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL). ASH Annual Meeting Abstracts. Blood 108, (2006) (Abstract 315).
69. Romaguera JE, Fayad L, Rodriguez MA et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J. Clin. Oncol. 23, 7013-7023 (2005).
70. Vose J, Loberiza F, Bierman P, Bociek G, Armitage J. Mantle cell lymphoma (MCL): induction therapy with HyperCVAD/ high-dose methotrexate and cytarabine (M-C) ({+/-}rituximab) improves results of autologous stem cell transplant in first remission. J. Clin. Oncol. 24, (2006) (Abstract 7511).
71. Till BG, Gooley TA, Crawford N et al. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk. Lymphoma 49, 1062-1073 (2008).
72. Vandenberghe E, de Elvara C, Loberiza F et al. Outcome of autologous transplantation for mantle cell lymphoma: a study of the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant registries. Br. J. Haematol. 120, 793-800 (2003).
73. Gianni AM, Magni M, Martelli M et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximabpurged stem cell autografting (R-HDS regimen). Blood 102, 749-755 (2003).
74. Ganti AK, Bierman PJ, Lynch JC, Bociek RG, Vose JM, Armitage JO. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann. Oncol. 16, 618-624 (2005).
75. Vigouroux S, Gaillard F, Moreau P, Harousseau JL, Milpied N. High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica 90, 1580-1582 (2005).
76. Dreyling M, Lenz G, Hoster E et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105, 2677-2684 (2005).
77. Thieblemont C, Antal D, Lacotte-Thierry L et al. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 104, 1434-1441(2005).
78. Laudi N, Arora M, Burns L et al. Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma. Am. J. Hematol. 81, 519-524 (2006).
79. Evens AM, Winter JN, Hou N et al. A Phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br. J. Haematol. 140, 385-393 (2008).
80. Geisler CH, Kolstad A, Laurell A et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized Phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112, 2687-2693 (2008).
81. Tam CS, Bassett R, Ledesma C et al. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113(18), 4144-4152 (2009).
82. Dreger P, Rieger M, Seyfarth B et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 92, 42-49 (2007).
83. Gopal AK, Rajendran JG, Petersdorf SH et al. High-dose chemoradioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99, 3158-3162 (2002).
84. Khouri IF, Lee MS, Saliba RM et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J. Clin. Oncol. 21, 4407-4412 (2003).
85. Maris MB, Sandmaier BM, Storer BE et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104, 3535-3542 (2004).
86. Savage KJ. Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am. Soc. Hematol. Educ. Program 2008(1), 280-288 (2008).
87. Rodriguez J, Conde E, Gutierrez A et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann. Oncol. 18, 652-657 (2007).
88. Feyler S, Prince HM, Pearce R et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 40, 443-450 (2007).
89. Corradini P, Tarella C, Zallio F et al. Longterm follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20, 1533-1538 (2006).
90. Reimer P, Rudiger T, Geissinger E et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J. Clin. Oncol. 27, 106-113 (2009).
91. d'Amore F, Relander T, Lauritzsen G et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL) -a Phase II study of the Nordic Lymphoma Group (NLG). ASH Annual Meeting Abstracts. Blood 108, (2006) (Abstract 401).
92. Mercadal S, Briones J, Xicoy B et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann. Oncol. 19, 958-963 (2008).
93. Rodriguez J, Caballero MD, Gutierrez A et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GELTAMO experience. Ann. Oncol. 14, 1768-1775 (2003).
94. Kewalramani T, Zelenetz AD, Teruya-Feldstein J et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br.J. Haematol. 134, 202-207 (2006).
95. Rodriguez J, Conde E, Gutierrez A et al. The adjusted International Prognostic Index and {β}-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 92, 1067-1074 (2007).
96. Nickelsen M, Canals C, Schmitz N et al. Mature T-cell lymphoma patients show high relapse rates after high-dose therapy followed by autologous transplantation. Presentated at: 10th International Conference on Malignant Lymphoma. Lugano, Switzerland, 4-7 June 2008 (Abstract 095).
97. Corradini P, Dodero A, Zallio F et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J. Clin. Oncol. 22, 2172-2176 (2004).
98. Gutierrez A, Caballero MD, Perez-Manga G, Rodriguez J. Hematopoietic SCT for peripheral T-cell lymphoma. Bone Marrow Transplant. 42, 773-781 (2008).
99. Le Gouill S, Milpied N, Buzyn A et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J. Clin. Oncol. 26, 2264-2271 (2008).
100. Rodrigues CA, Sanz G, Brunstein CG et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol. 27, 256-263 (2009).